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Figure S1, related to Figure 1.
A-B. Electron Microscopy images of wild-type mouse pancreatic tissue with its ER exhibiting a 
thin, ribbon-like structure (A) and PKO mouse pancreatic tissue showing gross expansion of the ER 
(B).
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Figure S2, related to Figure 2.
A. MIN6 cells treated for 4, 8, or 24 hrs. with 1µM PERKi (Pi). .  The methionine analog HPG (50 μM) was 
added 90 minutes before harvest. Newly synthesized proteins were quantified by fluorescence detection of 
the incorporated derivatized methionine using ImageJ software as described in Experimental Procedures. 
Quantification represents n=4 per treatment. Statistical significance was calculated relative to the non-
impacted control; *p≤0.05, **p<0.01.
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Figure S3, related to Figure 4.
A. mRNA expression levels quantified in MIN6 cells treated with 1μM PERKi. Quantification represents 
n=4 per treatment. Statistical significance is calculated relative to 0 hr. control; *p≤0.05, ***p<0.001.
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Figure S4, related to Figure 5.
A-J. Immuno-detection of DAPI (blue), proinsulin (red), 
BiP (green), and RCAS1(a Golgi-specific marker; 
magenta) images in INS1-832/13 cells treated for 24 
hours with 1μM PERKi or equal volume of DMSO.  
Cells were imaged on a high-resolution microscope to 
show increased co-localization of proinsulin and BiP 
staining as the ER becomes distended and the cell 
becomes impacted under PERKi conditions. White 
arrowhead indicated impacted cell. Scale bar = 10µm.
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Figure S5, related to Figure 6.
A. INS1 832/13 cells treated for 24 hrs. with 500nM PERKi (Pi). Puromycin (10μg/mL) was added 15 
minutes prior to harvest. Incorporation of puromycin into newly synthesized total protein was detected first 
by blotting with anti-puromycin. Puromycin-incorporated newly synthesized proinsulin was visualized by 
reprobing the same blots with anti-C-peptide. A representative blot is shown with quantification representing 
n=4 per treatment. Statistical significance is calculated relative to the AdV-GFP/DMSO control; #p=0.07, 
*p≤0.05, and ***p≤0.001.
B. mRNA expression levels in INS1 832/13 cells relative to control cells. Cells were infected with 500 MOI 
or 3000 MOI of adenovirus for 8 and 2 hrs, respectively, and media was replaced with fresh media. Cells 
were then treated for 24 hrs. with 500nM PERKi. Quantification represents n=4 per treatment. Statistical 
significance is calculated relative to the AdV-GFP/DMSO control for each MOI; *p≤.05, **p≤0.01, and 
***p≤0.001.
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Figure S6, related to Figure 6.
A. INS1 832/13 cells treated for 24 hrs. with 1μM PERKi and treated as indicated with 0.5μg/mL 
Subtilase cytotoxin (SubAB). A representative blot is shown with quantification representing n=4 per 
treatment.
B. INS1 832/13 cells treated with SubAB in combination with PERKi. Proinsulin and DAPI were 
detected by immunocytochemistry, and Impacted-ER were counted as a frequency of total cells. 
Quantification represents n=4 per treatment. Statistical significance was calculated relative to the 60 
minute Mutant control; ***p<0.001.
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Figure S7.
A. INS1 832/13 cells treated for 24 hrs. with 500nM PERKi and 50μM Gz. Quantification represents n=4 
per treatment. Statistical significance is calculated relative to PERKi treatment; ***p<0.001.
B. INS1 832/13 cells treated for 24 hrs. with 500nM PERKi and 50μM Gz. HMW protein aggregates 
were pelleted and electrophoresed as described in Fig. 1G. Representative blots are shown with 
quantification representing n=3 per treatment. Statistical significance is calculated relative to the DMSO 
control or as indicated; **p<0.01, ***p<0.001.
C. MIN6 cells treated for 1 hr. with 500nM PERKi and 50μM Gz. Puromycin (10μg/mL) was added 15 
minutes prior to harvest to measure newly synthesized protein. A representative blot is shown with 
quantification representing n=3 per treatment. Statistical significance is calculated relative to the DMSO 
control; *p≤0.05, **p<0.01, ***p<0.001.
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SUPPLEMENTARY TABLES 
TABLE S1: Mouse primers used for qPCR 
Gene Forward Primer Reverse Primer 
Actin 5′-GCCCTGAGGCTCTTTTCC-3′ 5′-TGCCACAGGATTCCATACCC-3′ 
Gapdh 5′-GGAGCGAGACCCCACTAACA-3′ 5′-ACATACTCAGCACCGGCCTC-3′ 
Erp57 5′-GGCGGATGCAACATATCACC-3’ 5′-TGTGGTTCGTACTGTCCCCC-3’ 
Bip 5′-GCTTCGTGTCTCCTCCTGAC-3′ 5′-TAGGAGTCCAGCAACAGGCT-3′ 
Erp72 5′-TTCCACGTGATGGATGTTCAG-3′ 5′-AGTCTTACGATGGCCCACCA-3′ 
Ero1B 5’-TGATTCGCAGGACCACTTTTG-3’ 5’-TAGCCAGTGTACCGTTCCGG-3’ 
Pdi 5’-TTGCTGGCAGCAGAGGCTAT-3’ 5’-GACCACCCCATCTTTGTCCA-3’ 
 
TABLE S2: Rat primers used for qPCR 
Gene Forward Primer Reverse Primer 
Actin 5′-ATCCTGGCCTCACTGTCCAC-3′ 5′-CTAGAAGCATTTGCGGTGCA-3′ 
Gapdh 5′-CACCACCAACTGCTTAGCCC-3′ 5′-TGGCATGGACTGTGGTCATG-3′ 
Erp72 5′-TGGCATGGACTGTGGTCATG-3′ 5′-TCATGGTAAGGTGCCGAGG-3′ 
Chop 5’-CCGGTCCAATTACAGTCATGG-3’ 5’-TCTCAAAGGCGAAAGGCAGA-3’ 
Gadd34 5’-CTACAGCCCCTTCACCTGCA-3’ 5’-CACCACCTCCCCAACTTTCTT-3’ 
Xbp1-spliced 5’-ATCCATGGGAAGATGTTCTGG-3’ 5’-CTGAGTCCGAATCAGGTGCAG-3’ 
Xbp1-total 5’-CCCTTCTCCCTTCAGCGAC-3’ 5’-CGTTGGCAAAAGTGTCCTCC-3’ 
Bip 5’-AACCAAGACATTTGCCCCAG-3’ 5’-GCATGGGTGACCTTCTTTCC-3’ 
Pdi 5’-GGACTCAAGCGAAGTGACGG-3’ 5’-TCTGCTGCCAGCAAGAACTG-3’ 
Erp57 5’-CGAAAACTTCGAGAGTCGCG-3’ 5’-GCAAGCCTCTTGCAATGTCC-3’ 
Ero1B 5’-TCTCCTGCTGCACAGTATGTGG-3’ 5’-AGTGTACCGTTCCGGGTTCA-3’ 
Atf6 5’-CCAGCAGAAAACCCGCATT-3’ 5’-GAATTCGAGCCCTGTTCCAG-3’ 
 
SUPPLEMENTARY EXPERIMENTAL PROCEDURES: 
 
TEM —Pancreas tissues was isolated and initially fixed in 2.5% glutaraldehyde, 4% paraformaldehyde in 
0.1 M sodium cacodylate buffer. Secondary fixation was with 1% osmium tetroxide in 0.1 M sodium 
cacodylate buffer. Samples were then stained with 2% uranyl acetate and dehydrated through an ethanol 
and acetone series. The samples were infiltrated and embedded in Spurr’s resin over several days and 
polymerized at 60°C. Transmission electron microscopy (TEM) samples were sectioned using a diamond 
knife (70 nm thick) and stained with uranyl acetate and lead citrate. Images were captured on a JEOL 
1200 EXII TEM microscope.  
The SUnSET method — In order to quantify new global and proinsulin synthesis as previously described 
(73,74), 10μg/ml puromycin was added 15 minutes before cells were harvested.  Western blot was 
performed as described below and proteins were probed with mouse anti-puromycin primary antibody 
overnight at 4°C.  After washing with TBST, IR800 anti-mouse secondary antibody was used (1:20000) 
for visualization of newly synthesized protein using a LI-COR Odyssey scanner and quantified using NIH 
ImageJ software. 
 
Isolation of high molecular weight proinsulin aggregates— Cells were washed in ice-cold 1X PBS 
containing 2mM EDTA and 10mM N-ethylmaleamide (Sigma). Cells were then lysed on ice for 10 
minutes in an ice-cold buffer containing TBSN (20mM HEPES pH 7.5, 150mM NaCl. 1% Triton X100, 
1mM EDTA) and wash buffer mixed at ratio of 2:5 to which 1X Protease Inhibitor Cocktail (Sigma) was 
added. Lysates were centrifuged through a QiaShredder (Qiagen) for 2 minutes at 10,0000 x g, 4oC to 
break up DNA. Total protein quantification of the lysates was measured via Bradford assay and loading 
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volumes were adjusted accordingly.  Equal lysates were pelleted through a 50% sucrose cushion (20mM 
HEPES pH7.5, 100mM NaCl, 50% sucrose w/v) at 100,000 x g for 45 minutes at 4oC in a Beckman 
Optimax TLX benchtop ultracentrifuge using a TLA 120.2 rotor. Care was taken to mix the lysates with 
any material that might have precipitated prior to differential centrifugation to ensure that insoluble 
aggregates were uniformly layered onto the sucrose cushion. Pellets were washed twice with RIPA buffer 
followed by centrifugation at 10,000rpm for 10 minutes at 4oC and then dissolved in 1X urea-PAGE 
sample buffer (9.6 M urea, 12% glycerol, 1.36% SDS, 40 mM Tris, pH 6.8) with or without beta-
mercaptoethanol. All samples were boiled for 5-7 minutes prior to loading on 4-12% Novex NuPage Bis-
Tris Midi Gels (Thermo-Fisher). 
